CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
400 µg Brimonidine Tartrate Implant +3 moredrug
Likely dose
400 µg Brimonidine Tartrate Implantfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00661479
NCT00661479Phase 2Completed
CompareCT.gov

An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa

Allergan·interventional·Posted Apr 18, 2008·Updated Apr 24, 2013

In Brief

A Phase 2 clinical trial evaluating 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, and 2 other interventions for Retinitis Pigmentosa. Completed, enrolled 21 participants across 4 sites in 4 countries.

Detailed Summary

This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinitis Pigmentosa
CountriesFrance, Germany, Portugal, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 18, 2008
Enrollment StartJul 1, 2008
Primary CompletionDec 1, 2009
Study CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.2 years ago

Interventions

400 µg Brimonidine Tartrate Implantdrug

400 µg brimonidine tartrate implant in the study eye on Day 1.

200 µg Brimonidine Tartrate Implantdrug

200 µg brimonidine tartrate implant in the study eye on Day 1.

100 µg Brimonidine Tartrate Implantdrug

100 µg brimonidine tartrate implant in the study eye on Day 1.

Sham (no implant)other

Sham in the fellow eye on Day 1.